Korro Bio, Inc. Common Stock

KRRONASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
10.72 USD
↘ 0.46 (4.11%)AT CLOSE (11:59 AM EDT)
10.57
↘ 0.15 (1.40%)
POST MARKET (AS OF 07:52 PM EDT)
Post Market
AS OF 07:52 PM EDT
10.57
↘ 0.15 (1.40%)
🔴Market: CLOSED
Open?$11.09
High?$11.28
Low?$10.46
Prev. Close?$11.18
Volume?187.7K
Avg. Volume?122.6K
VWAP?$10.76
Rel. Volume?1.53x
Bid / Ask
Bid?$10.51 × 100
Ask?$10.63 × 100
Spread?$0.12
Midpoint?$10.57
Valuation & Ratios
Market Cap?154.6M
Shares Out?14.4M
Float?10.6M
Float %?73.2%
P/E Ratio?N/A
P/B Ratio?1.29
EPS?-$7.87
Dividend?0.00%
Ex-Dividend?N/A

Korro Bio, Inc. Common Stock (KRRO) is currently trading at $10.72. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, KRRO trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
49
Market Cap
154.6M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.korrobio.com
Listed
2023-11-06
Address
60 FIRST STREET
CAMBRIDGE, MA 02141
Phone: 617-468-1999
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
23
Piotroski F-Score?0/9Weak
Altman Z-Score?-3.02Distress
Confidence?51%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?11.32%High
Short Interest?1.2M
Days to Cover?11.5
Free Float10.6M
Avg Daily Volume104.3K
Settlement Date2026-05-15
Financial Health
Current Ratio?8.13Strong
Quick Ratio?8.13Strong
Cash Ratio?4.17Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
91
1.29CHEAP▾
P/S?
Peers
100
S&P
3
40.24HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.2CHEAP▾
EV/Sales?
Peers
100
S&P
3
24.18HIGH▾
Returns & Efficiency
ROE?
S&P
3
-94.9%WEAK▾
ROA?
S&P
3
-61.8%WEAK▾
Cash Flow & Enterprise
FCF?$-70603000
Enterprise Value?$92.9M
Fundamentals ratios updated end of day
MarketsMoversWatchlist